21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis.

          Related collections

          Author and article information

          Journal
          N Engl J Med
          The New England journal of medicine
          Massachusetts Medical Society
          1533-4406
          0028-4793
          Jun 12 2014
          : 370
          : 24
          Affiliations
          [1 ] From the Swedish Medical Center and University of Washington, Seattle (P.J.M.); Oregon Health and Science University, Portland (A.D.); Stanford University, Palo Alto (M.C.G.), Desert Medical Advances, Palm Desert (M.W.G.), and Amgen, Thousand Oaks (R.N., J.Y.F., N.E., A.N.) - all in California; University of Rochester Medical Center, Rochester, NY (C.T.R.); and Laval University, Quebec, QC, Canada (A.D.B.).
          Article
          10.1056/NEJMoa1315231
          24918373
          240d1f31-377a-4d3a-a071-56e53442cb91
          History

          Comments

          Comment on this article